23 research outputs found
Proinflammatory adipocytokines induce TIMP-1 expression in 3T3-L1 adipocytes
AbstractTissue inhibitor of metalloproteinase (TIMP)-1 is an adipocyte-secreted protein upregulated in obesity which promotes adipose tissue development. Furthermore, the proinflammatory adipocytokines tumor necrosis factor α (TNFα) and interleukin (IL)-6 induce insulin resistance, and plasma concentrations are increased during weight gain. In the current study, the impact of TNFα and IL-6 on TIMP-1 mRNA and protein expression was determined in 3T3-L1 adipocytes. Interestingly, TNFα and IL-6 induced TIMP-1 protein secretion more than 3- and 2-fold, respectively. Furthermore, TIMP-1 mRNA was upregulated in a time- and dose-dependent fashion. Inhibitor experiments suggested that nuclear factor κB and p44/42 mitogen-activated protein kinase are involved in both, basal and adipocytokine-induced TIMP-1 expression. Moreover, the thiazolidinedione troglitazone partly reversed TNFα- but not IL-6-induced TIMP-1 synthesis. Taken together, we demonstrate that TIMP-1 expression is selectively upregulated in fat cells by proinflammatory adipocytokines and might play a role in maintaining adipose tissue mass in obesity
Increased Growth Differentiation Factor 15 in Patients with Hypoleptinemia-Associated Lipodystrophy
Objective. Similar to obesity, lipodystrophy (LD) causes adipose tissue dysfunction and severe
metabolic complications. Growth differentiation factor 15 (GDF15) belongs to the transforming growth
factor superfamily and is dysregulated in metabolic disease including obesity and diabetes mellitus.
Circulating levels in LDand the impact of leptin treatment have not been investigated so far.Material and
Methods. GDF15 serum levels were quantified in 60 LD patients without human immunodeficiency
virus infection and 60 controlsmatched for age, gender, and bodymass index. The impact ofmetreleptin
treatment on circulating GDF15 was assessed in a subgroup of patients. GDF15 mRNA expression was
determined in metabolic tissues of leptin-deficient lipodystrophic aP2-nSREBP1c-Tg mice, obese ob/ob
mice, and control C57Bl6 mice. Results. Median GDF15 serum concentrations were significantly higher
in LD patients (819 ng/L) as compared to the control group (415 ng/L) (p < 0.001). In multiple linear
regression analysis, an independent and positive association remained between GDF15 on one hand and
age, patient group, hemoglobin A1c, triglycerides, and C-reactive protein on the other hand. Moreover,
there was an independent negative association between GFD15 and estimated glomerular filtration rate.
Circulating GDF15 was not significantly affected by metreleptin treatment in LD patients. Gdf15 was
upregulated in leptin-deficient lipodystrophic mice as compared to controls. Moreover, Gdf15 mRNA
expression was downregulated by leptin treatment in lipodystrophic and obese animals. Conclusions.
Serum concentrations of GDF15 are elevated in LD patients and independently associated withmarkers
of metabolic dysfunction. Gdf15 expression is higher in lipodystrophic mice and downregulated by
leptin treatment
Increased Growth Differentiation Factor 15 in Patients with Hypoleptinemia-Associated Lipodystrophy
Objective. Similar to obesity, lipodystrophy (LD) causes adipose tissue dysfunction and severe
metabolic complications. Growth differentiation factor 15 (GDF15) belongs to the transforming growth
factor superfamily and is dysregulated in metabolic disease including obesity and diabetes mellitus.
Circulating levels in LDand the impact of leptin treatment have not been investigated so far.Material and
Methods. GDF15 serum levels were quantified in 60 LD patients without human immunodeficiency
virus infection and 60 controlsmatched for age, gender, and bodymass index. The impact ofmetreleptin
treatment on circulating GDF15 was assessed in a subgroup of patients. GDF15 mRNA expression was
determined in metabolic tissues of leptin-deficient lipodystrophic aP2-nSREBP1c-Tg mice, obese ob/ob
mice, and control C57Bl6 mice. Results. Median GDF15 serum concentrations were significantly higher
in LD patients (819 ng/L) as compared to the control group (415 ng/L) (p < 0.001). In multiple linear
regression analysis, an independent and positive association remained between GDF15 on one hand and
age, patient group, hemoglobin A1c, triglycerides, and C-reactive protein on the other hand. Moreover,
there was an independent negative association between GFD15 and estimated glomerular filtration rate.
Circulating GDF15 was not significantly affected by metreleptin treatment in LD patients. Gdf15 was
upregulated in leptin-deficient lipodystrophic mice as compared to controls. Moreover, Gdf15 mRNA
expression was downregulated by leptin treatment in lipodystrophic and obese animals. Conclusions.
Serum concentrations of GDF15 are elevated in LD patients and independently associated withmarkers
of metabolic dysfunction. Gdf15 expression is higher in lipodystrophic mice and downregulated by
leptin treatment
Increased Growth Differentiation Factor 15 in Patients with Hypoleptinemia-Associated Lipodystrophy
Objective. Similar to obesity, lipodystrophy (LD) causes adipose tissue dysfunction and severe metabolic complications. Growth differentiation factor 15 (GDF15) belongs to the transforming growth factor β superfamily and is dysregulated in metabolic disease including obesity and diabetes mellitus. Circulating levels in LD and the impact of leptin treatment have not been investigated so far. Material and Methods. GDF15 serum levels were quantified in 60 LD patients without human immunodeficiency virus infection and 60 controls matched for age, gender, and body mass index. The impact of metreleptin treatment on circulating GDF15 was assessed in a subgroup of patients. GDF15 mRNA expression was determined in metabolic tissues of leptin-deficient lipodystrophic aP2-nSREBP1c-Tg mice, obese ob/ob mice, and control C57Bl6 mice. Results. Median GDF15 serum concentrations were significantly higher in LD patients (819 ng/L) as compared to the control group (415 ng/L) (p < 0.001). In multiple linear regression analysis, an independent and positive association remained between GDF15 on one hand and age, patient group, hemoglobin A1c, triglycerides, and C-reactive protein on the other hand. Moreover, there was an independent negative association between GFD15 and estimated glomerular filtration rate. Circulating GDF15 was not significantly affected by metreleptin treatment in LD patients. Gdf15 was upregulated in leptin-deficient lipodystrophic mice as compared to controls. Moreover, Gdf15 mRNA expression was downregulated by leptin treatment in lipodystrophic and obese animals. Conclusions. Serum concentrations of GDF15 are elevated in LD patients and independently associated with markers of metabolic dysfunction. Gdf15 expression is higher in lipodystrophic mice and downregulated by leptin treatment
Brown adipose tissue (BAT) specific vaspin expression is increased after obesogenic diets and cold exposure and linked to acute changes in DNA-methylation
Objective: Several studies have demonstrated anti-diabetic and anti-obesogenic properties of visceral adipose tissue-derived serine protease inhibitor (vaspin) and so evoked its potential use for treatment of obesity-related diseases. The aim of the study was to unravel physiological regulators of vaspin expression and secretion with a particular focus on its role in brown adipose tissue (BAT) biology. Methods: We analyzed the effects of obesogenic diets and cold exposure on vaspin expression in liver and white and brown adipose tissue (AT) and plasma levels. Vaspin expression was analyzed in isolated white and brown adipocytes during adipogenesis and in response to adrenergic stimuli. DNA-methylation within the vaspin promoter was analyzed to investigate acute epigenetic changes after cold-exposure in BAT. Results: Our results demonstrate a strong induction of vaspin mRNA and protein expression specifically in BAT of both cold-exposed and high-fat (HF) or high-sugar (HS) fed mice. While obesogenic diets also upregulated hepatic vaspin mRNA levels, cold exposure tended to increase vaspin gene expression of inguinal white adipose tissue (iWAT) depots. Concomitantly, vaspin plasma levels were decreased upon obesogenic or thermogenic triggers. Vaspin expression was increased during adipogenesis but unaffected by sympathetic activation in brown adipocytes. Analysis of vaspin promoter methylation in AT revealed lowest methylation levels in BAT, which were acutely reduced after cold exposure. Conclusions: Our data demonstrate a novel BAT-specific regulation of vaspin gene expression upon physiological stimuli in vivo with acute epigenetic changes that may contribute to cold-induced expression in BAT. We conclude that these findings indicate functional relevance and potentially beneficial effects of vaspin in BAT function. Keywords: Brown adipose tissue, Browning, Cold exposure, DNA methylation, High-fat diet, High-sucrose diet, SerpinA12, Thermogenesis, UCP1, Vaspi
Secretory products from human adipocytes stimulate proinflammatory cytokine secretion from human endothelial cells
Hyperplasia and hypertrophy of fat cells can be found in obesity and increased adiposity is associated with endothelial dysfunction as an early event of atherosclerosis. However, it is unclear whether human adipocytes directly influence endothelial protein secretion. To study the crosstalk between fat and endothelial cells, human umbilical venous endothelial cells (HUVECs) were cultured in infranatants (Adipo) of primary differentiated human adipocytes. Interestingly, significantly increased secretion of 23 cytokines and chemokines from HUVECs was detected in four independent experiments after Adipo stimulation by protein array analysis detecting a total of 174 different proteins. Among those, time-dependent Adipo-induced upregulation of cytokine secretion in HUVECs was confirmed by ELISA for interleukin (IL)-8, monokine induced by gamma interferon, macrophage inflammatory protein (MIP)-1beta, MIP-3alpha, monocyte chemoattractant protein-1, and IL-6. Factors besides adiponectin, leptin, resistin, and tumor necrosis factor alpha appear to mediate these stimulatory effects. Our findings suggest that endothelial cell secretion is significantly influenced towards a proinflammatory pattern by adipocyte-secreted factors
Adipocyte and epidermal fatty acid-binding protein serum concentrations in patients with lipodystrophy
Leptin restores markers of female fertility in lipodystrophy
Objectives: Female reproductive dysfunction occurs in patients with pathological loss of adipose tissue, i.e. lipodystrophy (LD). However, mechanisms remain largely unclear and treatment effects of adipocyte-derived leptin have not been assessed in LD animals. Methods: In the current study, C57131/6 LD mice on a low-density lipoprotein receptor knockout background were treated with leptin or saline for 8 weeks and compared to non-LD controls. Results: The number of pups born was 37% lower in breeding pairs consisting of LD female mice x non-LD male mice (n = 3.3) compared to LD male mice x non-LD female mice (n = 5.2) (p < 0.05). Mean uterus weight was significantly lower in the saline-treated LD group (18.8 mg) compared to non-LD controls (52.9 mg; p < 0.0001) and increased significantly upon leptin treatment (46.5 mg; p < 0.001). The mean number of corpora lutea per ovary was significantly lower in saline-treated LD animals compared to non-LD controls (p < 0.01) and was restored to non-LD control levels by leptin (p < 0.05). Mechanistically, mRNA expression of ovarian follicle stimulating hormone receptor (p < 0.01) and estrogen receptor beta (p < 0.05), as well as of pituitary luteinizing hormone beta subunit (p < 0.001) and follicle-stimulating hormone beta subunit (p < 0.05), was significantly up regulated in LD mice compared to non-LD controls. In addition, mean time to vaginal opening as a marker of puberty onset was delayed by 12.5 days in LD mice (50.9 days) compared to non-LD controls (38.4 days; p < 0.001). Conclusions: Female LD animals show impaired fertility which is restored by leptin. Future studies should assess leptin as a subfertility treatment in human leptin-deficiency disorders